Metastatic Uveal Melanoma Latest Advances

ImmTAC: A Novel Platform of T-Cell Receptor-Based Soluble Bispecifics.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 10, 2026

First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study.

Journal: Journal for immunotherapy of cancer

Published: April 09, 2026

Percutaneous hepatic perfusion versus best alternative care as treatment for metastatic uveal melanoma: A meta-analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 03, 2026

Correction to: Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.

Journal: The oncologist

Published: March 23, 2026

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 02, 2026

Current Therapies and Potential Strategies for Uveal Melanoma.

Journal: Drugs and drug candidates

Published: February 25, 2026

"BAP1 Loss Induces Senescence and Enhances the Response to Radiation Therapy and Senolytics".

Journal: bioRxiv : the preprint server for biology

Published: February 23, 2026

Fungal intratumoral dysbiosis promoting PD-L1 expression in metastatic uveal melanoma with ocular inflammatory mimicry.

Journal: Annals of medicine and surgery (2012)

Published: February 16, 2026

Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis.

Journal: Frontiers in oncology

Published: February 15, 2026

Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial).

Journal: Journal for immunotherapy of cancer

Published: February 10, 2026

CDK6/4 inactivates BAP1 deubiquitinase destabilizing VHL to promote metastatic colonization in liver.

Journal: Molecular cancer

Published: February 02, 2026

Escape From Synthetic T Cell Activator Tebentafusp by Genomic HLA Loss: A Case Report.

Journal: HLA

Published: February 01, 2026

Metastatic Uveal Melanoma Latest Advances

Find the Latest Research About Metastatic Uveal Melanoma

ImmTAC: A Novel Platform of T-Cell Receptor-Based Soluble Bispecifics.

ImmTAC: A Novel Platform of T-Cell Receptor-Based Soluble Bispecifics.

First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study.

First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study.

Percutaneous hepatic perfusion versus best alternative care as treatment for metastatic uveal melanoma: A meta-analysis.

Percutaneous hepatic perfusion versus best alternative care as treatment for metastatic uveal melanoma: A meta-analysis.

Correction to: Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.

Correction to: Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma.

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma.

Current Therapies and Potential Strategies for Uveal Melanoma.

Current Therapies and Potential Strategies for Uveal Melanoma.

"BAP1 Loss Induces Senescence and Enhances the Response to Radiation Therapy and Senolytics".

"BAP1 Loss Induces Senescence and Enhances the Response to Radiation Therapy and Senolytics".

Fungal intratumoral dysbiosis promoting PD-L1 expression in metastatic uveal melanoma with ocular inflammatory mimicry.

Fungal intratumoral dysbiosis promoting PD-L1 expression in metastatic uveal melanoma with ocular inflammatory mimicry.

Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis.

Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis.

Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial).

Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial).

CDK6/4 inactivates BAP1 deubiquitinase destabilizing VHL to promote metastatic colonization in liver.

CDK6/4 inactivates BAP1 deubiquitinase destabilizing VHL to promote metastatic colonization in liver.

Escape From Synthetic T Cell Activator Tebentafusp by Genomic HLA Loss: A Case Report.

Escape From Synthetic T Cell Activator Tebentafusp by Genomic HLA Loss: A Case Report.